256 related articles for article (PubMed ID: 34486371)
1. Bispecific Antibody Designed for Targeted NK Cell Activation and Functional Assessment for Biomedical Applications.
Song AY; Kim H; Kim JM; Hwang SH; Ko DH; Kim HS
ACS Appl Mater Interfaces; 2021 Sep; 13(36):42370-42381. PubMed ID: 34486371
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
3. Production of a novel bispecific protein ULBP1×CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells.
Zhao Q; Pang J; Yan F; Jiang Y; Cui D; Liu J; Jing L; Li Y; Liu Z; Tao L; Zhao X; Diao A
Protein Expr Purif; 2021 Feb; 178():105783. PubMed ID: 33122138
[TBL] [Abstract][Full Text] [Related]
4. XLP1 inhibitory effect by 2B4 does not affect DNAM-1 and NKG2D activating pathways in NK cells.
Meazza R; Tuberosa C; Cetica V; Falco M; Loiacono F; Parolini S; Micalizzi C; Moretta A; Mingari MC; Moretta L; Bottino C; Aricò M; Pende D
Eur J Immunol; 2014 May; 44(5):1526-34. PubMed ID: 24496997
[TBL] [Abstract][Full Text] [Related]
5. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome.
Tangye SG; Phillips JH; Lanier LL; Nichols KE
J Immunol; 2000 Sep; 165(6):2932-6. PubMed ID: 10975798
[TBL] [Abstract][Full Text] [Related]
6. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
Kiefer A; Prüfer M; Röder J; Pfeifer Serrahima J; Bodden M; Kühnel I; Oberoi P; Wels WS
Cells; 2024 Jan; 13(3):. PubMed ID: 38334638
[TBL] [Abstract][Full Text] [Related]
7. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
[TBL] [Abstract][Full Text] [Related]
8. WhatSAP - 2B4 sends mixed messages in the absence of SAP.
Watzl C; Claus M
Eur J Immunol; 2014 May; 44(5):1281-4. PubMed ID: 24659462
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
10. A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.
Chan WK; Kang S; Youssef Y; Glankler EN; Barrett ER; Carter AM; Ahmed EH; Prasad A; Chen L; Zhang J; Benson DM; Caligiuri MA; Yu J
Cancer Immunol Res; 2018 Jul; 6(7):776-787. PubMed ID: 29769244
[TBL] [Abstract][Full Text] [Related]
11. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.
von Strandmann EP; Hansen HP; Reiners KS; Schnell R; Borchmann P; Merkert S; Simhadri VR; Draube A; Reiser M; Purr I; Hallek M; Engert A
Blood; 2006 Mar; 107(5):1955-62. PubMed ID: 16210338
[TBL] [Abstract][Full Text] [Related]
12. 2B4 (CD244)-mediated activation of cytotoxicity and IFN-gamma release in human NK cells involves distinct pathways.
Chuang SS; Kumaresan PR; Mathew PA
J Immunol; 2001 Dec; 167(11):6210-6. PubMed ID: 11714782
[TBL] [Abstract][Full Text] [Related]
13. Assessment of NK Cell Activity Based on NK Cell-Specific Receptor Synergy in Peripheral Blood Mononuclear Cells and Whole Blood.
Kim JM; Yi E; Cho H; Choi WS; Ko DH; Yoon DH; Hwang SH; Kim HS
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143099
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients.
Meazza R; Falco M; Marcenaro S; Loiacono F; Canevali P; Bellora F; Tuberosa C; Locatelli F; Micalizzi C; Moretta A; Mingari MC; Moretta L; Aricò M; Bottino C; Pende D
Eur J Immunol; 2017 Jun; 47(6):1051-1061. PubMed ID: 28386908
[TBL] [Abstract][Full Text] [Related]
15. 2B4-mediated activation of human natural killer cells.
Tangye SG; Cherwinski H; Lanier LL; Phillips JH
Mol Immunol; 2000 Jun; 37(9):493-501. PubMed ID: 11163399
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
17. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
Front Immunol; 2021; 12():731767. PubMed ID: 34691037
[TBL] [Abstract][Full Text] [Related]
18. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
[TBL] [Abstract][Full Text] [Related]
19. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
20. Defective NK cell activation in X-linked lymphoproliferative disease.
Benoit L; Wang X; Pabst HF; Dutz J; Tan R
J Immunol; 2000 Oct; 165(7):3549-53. PubMed ID: 11034354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
